First-line treatment of patients with HER2-positive metastatic breast cancer – 4 years of long-term follow-up data
Best Practice Nordic | Jun 2019 | | | ASCO 2019
Progression-free and overall survival were significantly improved with first line treatment with pertuzumab, trastuzumab, and docetaxel in 808 pts with HER2-positive metastatic breast cancer. OS was increased by an unprecedented 15.7 month. In this MEDtalk Sandra M. Swain present the end-of-study analysis with a median follow-up of 99 month (max 120 mo).